

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 24, 2025

KALS-1

RRID:CVCL_1323

Type: Cell Line

Proper Citation

(RRID:CVCL_1323)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1323

Proper Citation: (RRID:CVCL_1323)

Sex: Female

Defining Citation: [PMID:16232199](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: KALS-1

Synonyms: KALS1

Cross References: CLO:CLO_0009892, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:625, BioSample:SAMN03470951, BioSample:SAMN10987840, cancercellines:CVCL_1323, Cell_Model_Passport:SIDM00613, CGH-DB:142-1, ChEMBL-Cells:ChEMBL3308235, ChEMBL-Targets:ChEMBL2366155, Cosmic:687572, Cosmic:907271, Cosmic:2367530, Cosmic:2516020, Cosmic-CLP:907271, DepMap:ACH-000231, EGA:EGAS00001000978, GDSC:907271, GEO:GSM887194, GEO:GSM888267, GEO:GSM1669972, IARC_TP53:21426, JCRB:IFO50434, LiGeA:CCLE_316, LINCS_LDP:LCL-1380,

PharmacDB:KALS1_726_2019, PRIDE:PXD030304, Progenetix:CVCL_1323, PubChem_Cell_line:CVCL_1323, Wikidata:Q54899463

ID: CVCL_1323

Record Creation Time: 20250131T201119+0000

Record Last Update: 20250131T202624+0000

Ratings and Alerts

No rating or validation information has been found for KALS-1.

No alerts have been found for KALS-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Uchida S, et al. (2024) Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma. Neoplasia (New York, N.Y.), 50, 100982.

Hattori EY, et al. (2022) A RUNX-targeted gene switch-off approach modulates the BIRC5/PIF1-p21 pathway and reduces glioblastoma growth in mice. Communications biology, 5(1), 939.